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Abstract
Cytochrome P-450 function as mono-oxygenases and meta-
bolize xenobiotics. CYP1A1, a cytochrome P-450 enzyme,
bioactivates polycyclic aromatic hydrocarbons to reactive
metabolite(s) that bind to DNA and initiate carcinogenesis.
Northern and immunoblot analyses revealed constitutive
expression of Cyp1a1 and CYP1A1 in rat and human brain,
respectively. CYP1A1 mRNA and protein were localized pre-
dominantly in neurons of cerebral cortex, Purkinje and granule
cell layers of cerebellum and pyramidal neurons of CA1, CA2,
and CA3 subfields of the hippocampus. RT–PCR analyses
using RNA obtained from autopsy human brain samples
demonstrated the presence of a splice variant having a
deletion of 87 bp of exon 6. This splice variant was present in
human brain, but not in the liver from the same individual, and
was absent in rat brain and liver. Structural modeling indicated
broadening of the substrate access channel in the brain
variant. The study demonstrates the presence of a unique
cytochrome P-450 enzyme in human brain that is generated
by alternate splicing. The presence of distinct cytochrome
P-450 enzymes in human brain that are different from well-
characterized hepatic forms indicates that metabolism of
xenobiotics including drugs could occur in brain by pathways
different from those known to occur in liver.
Keywords: brain, CYP1A1, cytochrome P-450, drug meta-
bolism, mono-oxygenases.
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Cytochrome P-450 (P-450) superfamily of heme proteins is
involved in metabolism of a vast array of carcinogens, drugs,
and endogenous compounds. P-450 enzymes exist in mul-
tiple forms and are selectively induced or inhibited by a
variety of chemicals. They are known to exist in liver, the
major organ involved in P-450-mediated xenobiotic meta-
bolism (de Montellano 1986). However, the importance of
extrahepatic metabolism has been increasingly recognized,
especially with respect to its potential role in target organ
toxicity. This has prompted extensive investigations into the
xenobiotic metabolizing capability of extrahepatic organs
such as kidney, lung, brain, etc. in laboratory animals and
humans (Gram et al. 1986). Studies from our laboratory and
others have demonstrated the presence of a competent
microsomal P-450 system in the rodent (Anandatheerthava-
rada et al. 1990) and human brain (Ravindranath et al.
1989), and its ability to metabolize a variety of xenobiotics.
Multiple forms of P-450 enzymes, which are selectively
induced by 3-methyl cholanthrene, b-naphthoflavone, phe-
nobarbital, and ethanol are expressed in brain (Ravindranath
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1Individual cytochrome P-450 gene in human is represented as ‘CYP’
and rat as ‘Cyp’ followed by an Arabic number denoting family and an
alphabetical letter designating subfamily (CYP1A/Cyp1a). An Arabic
number is used to represent genes within a subfamily (e.g. human
CYP1A1 and rat Cyp1a1). Cytochrome P-450 protein is represented
with a prefix ‘P-450’ (P-450 1A1/P-450 1a1) in a similar manner. When
reference is made to both the rat and human forms, CYP1A1 and P-450
1A1 are used.
Abbreviations used: FISH, fluorescence in situ hybridization; ML,
molecular layer; P-450, cytochrome P-450; PBS, phosphate-buffered
saline; SDS–PAGE, sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis.
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and Boyd 1995). These studies have also demonstrated the
constitutive presence of several forms of P-450 enzymes
including 1A1/A2, 2B1/2B2, 2D6, 2E1, and P-450 3A in rat
and human brain (Anandatheerthavarada et al. 1990; Rav-
indranath and Boyd 1995). Because brain exhibits regional
and cellular heterogeneity it is important to determine the
localization of specific forms of P-450 as it would help to
understand the potential consequences of metabolism of
xenobiotics mediated by specific enzymes of P-450.
Cytochrome P-450 1A1, a member of the P-450 super-
family, is a major extrahepatic enzyme and is induced by
administration of 3-methylcholanthrene, b-naphthoflavone
(Gozukara et al. 1984) or 2,3,7,8-tetra chlorobenzo-p-dioxin
(Jones et al. 1986). P-450 1A1 contributes notably to the
toxicity of many carcinogens, especially polycyclic aromatic
hydrocarbons, as it is the principal enzyme that bioactivates
the inert hydrocarbons into DNA-binding reactive metabo-
lites (Park et al. 1996). The presence of P-450 1A1 in brain
could potentially play a role in the initiation of carcinogen-
esis in situ, as polycyclic aromatic hydrocarbons are
lipophilic and can cross the blood–brain barrier.
The expression of Cyp1a1 in rat brain (Anandatheerthav-
arada et al. 1990; Morse et al. 1998) and CYP1A1 in human
brain (Farin and Omiecinski 1993) has been demonstrated
using RT–PCR. However, relatively little is known about the
regional and cellular localization of P-450 1A1. Recent
studies have also shown that induction of the P-450 1A1
enzyme by polycyclic aromatic hydrocarbons increases the
generation of reactive oxygen species, which may cause
oxidative damage in brain (Strolin-Benedetti et al. 1999).
Therefore, the present study was undertaken to study the
constitutive expression and topographic distribution of this
enzyme at the mRNA and protein level in rat and human brain.
Materials and methods
Materials
cDNA to Cyp1a1 was obtained as gift from Dr Avadhani (Univ. of
Pennsylvania, Philadelphia, PA, USA). DIG-RNA labeling and
detection kit, antidigoxigenin Fab fragments linked to peroxidase
and alkaline phosphatase were purchased from Roche Biochemicals
(Indianapolis, IN, USA). The tyramide signal amplification kit was
obtained from New England Nuclear (Boston, MA, USA) and
Vectastain-ABC Elite kit was purchased from Vector Labs (Burlin-
game, CA, USA). All other chemicals and reagents were of
analytical grade and were obtained from Sigma Chemical Company
(St Louis, MO, USA) or Qualigens (Bangalore, India).
Animals
Male Wistar rats (3–4 months, 225–250 g) were obtained from the
Central Animal Research Facility of the National Institute of Mental
Health and Neurosciences. Animals had access to a pelleted diet
(Lipton India, Calcutta, India) and water ad libitium. All animal
experiments were carried out in accordance with the National
Institutes of Health guidelines for the care and use of laboratory
animals and were approved by the institutional ethics committee. All
efforts were made to minimize animal suffering, to reduce number
of animals used, and to utilize alternatives to in vivo techniques, if
available.
Human brain tissue
Human brain tissues were obtained at autopsy from traffic accident
victims with no known neurological or psychiatric disorders through
the Human Brain Tissue Repository, Department of Neuropathol-
ogy, NIMHANS. The Human Brain Tissue Repository has been
established to provide human post-mortem tissue to researchers in
India taking into due consideration all the ethical concerns of the
Government of India. Brain tissues from both male and female
subjects were used. The average age of the individuals was
24.76 ± 20.22 years and post-mortem delay between death and
autopsy was 7.3 ± 3.7 h. After autopsy, brain samples were washed
in ice-cold saline and dissected into different regions such as cortex,
hippocampus, striatum, midbrain, cerebellum, and thalamus based
on standard anatomical markings. All regions were flash-frozen and
stored at ) 70C immediately. Regions from each human brain were
thawed on ice and used for the preparation of microsomes as
described below. Microsomes were aliquoted and stored at ) 70C.
Preparation of microsomes
Animals were anesthetized with ether and perfused transcardially
with ice-cold Tris buffer (100 mM, pH 7.4) containing KCl (1.15%,
w/v) prior to decapitation and removal of the brain. Rat brain
regions (cortex, cerebellum, midbrain, hippocampus, and thalamus)
were dissected out using standard anatomical landmarks (Glowinski
and Iversen 1966). Rat and human brain regions were homogenized
using a Potter–Elvehjem homogenizer in 9 volumes of ice-cold Tris
Fig. 1 Northern blot analysis showing the constitutive expression of
Cyp1a1 and CYP1A1 mRNA in rat and human brain. Total RNA from
rat liver (a, lane1; 3 lg) and poly-(A+) RNA from rat brain cortex and
cerebellum (lane 2–3, 5 lg) and poly-(A+) RNA from autopsy human
brain cortex from three subjects (b, lanes 1–3, 5 lg) were electro-
phoresed under denaturing conditions. After transfer to nylon mem-
brane, the blots were hybridized with antisense riboprobe prepared
using cDNA to Cyp1a1. The mobility of the 18S and 28S ribosomal
RNA is indicated. The expression of Cyp1a1 in rat and CYP1A1 in
human brain was seen as bands close to the 18S ribosomal RNA
which nearly corresponds to the size of 1.6 Kb.
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buffer (0.1 mM), EDTA (0.1 mM), KCl (1.15%, w/v), phenyl methyl
sulfonyl fluoride (0.1 mM), butylated hydroxytoluene (22 lM),
glycerol (20%, v/v), aprotinin (0.001%, w/v), and leupeptin
(0.001%, w/v), previously bubbled with nitrogen (buffer A). The
homogenate was centrifuged at 17 000 g for 30 min at 4C.
Thereafter, the supernatant was centrifuged at 100 000 g for 1 h
to give the microsomal pellet. The pellet was suspended in a small
volume of buffer A, aliquoted, flash-frozen in liquid nitrogen, and
stored at ) 70C (Ravindranath and Anandatheerthavarada 1990).
The protein concentration was measured by the dye-binding method
(Bradford 1976).
Immunoblot analyses
Microsomal proteins from rat (50 lg) and human (50 lg) brain
regions were subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS–PAGE; Laemmli and Favre 1973).
Proteins were transferred from the gel to nitrocellulose membranes
(Towbin et al. 1979). Membranes were immunostained with
antiserum to rat liver P-450 1a1 (Anandatheerthavarada et al.
1990) followed by incubation with anti-rabbit IgG labeled with
alkaline phosphatase (Vector Laboratories). Immunostained bands
were detected using nitroblue tetrazolium and 5-bromo 4-chloro
3-indolyl phosphate as chromogens.
Northern blotting
The cDNA to rat liver Cyp1a1 was used for preparation of
riboprobes. Total RNA from rat liver and poly-(A)+RNA from rat
brain cortex and cerebellum and human brain cortex were extracted
as described by Chomezynski (1993). Total RNA and mRNA were
separated electrophoretically and transferred to positively charged
nylon membrane by capillary transfer (Kevil et al. 1997), UV cross-
linked and hybridized with digoxigenin-labeled antisense riboprobe
prepared using T7 RNA polymerase to Cyp1a1. Sense cRNA probe
was synthesized using SP6 RNA polymerase. Membrane was
hybridized overnight with digoxigenin-labeled sense and antisense
riboprobe at 50C, washed, incubated with antibody to digoxigenin
Fig. 2 Localization of Cyp1a1 mRNA in normal rat brain using fluor-
escent in situ hybridization. (a) The presence of Cyp1a1 mRNA in the
neurons of cerebral cortex. Bar ¼ 100 lm. (b) Intense fluorescence
was seen in the Purkinje neurons of the cerebellum hybridized with
antisense probe. Bar ¼ 25 lm. (c) Staining of the reticular neurons in
the midbrain showed the expression of the Cyp1a1 mRNA. Bar ¼
50 lm. (d) Expression of Cyp1a1 mRNA was seen in the neurons of
the striatum, although to a lesser extent than the neurons in the cer-
ebral cortex. Bar ¼ 50 lm. (e) The granule cell layer of the dentate
gyrus was intensely fluorescent showing the expression of Cyp1a1
mRNA. Intense fluorescence was seen in the CA1 pyramidal cell layer
of hippocampus. Staining of CA3 neurons is indicated by the arrow.
Bar ¼ 100 lm. (f) Cyp1a1 mRNA was observed in the thalamic
neurons. Bar ¼ 25 lm. (g) Intense fluorescence of glomeruli neurons
(arrow) shows the expression of Cyp1a1mRNA in the olfactory bulb.
Bar ¼ 50 lm. (h) The anterior horn cells of the spinal cord (arrow)
were intensely fluorescent indicating the substantial expression of
Cyp1a1. Bar ¼ 50 lm. (i) Control section of hippocampus hybridized
with the sense probe did not show any FITC fluorescent staining.
Bar ¼ 200 lm. (j) The control section of thalamic region hybridized
with sense probe did not reveal any FITC staining. Bar ¼ 200 lm.
(k) Control section of the olfactory bulb hybridized with the digoxigenin
labeled with sense probe counter stained with Evan’s blue. Bar ¼
200 lm. (l) Control section of spinal cord hybridized with the digoxo-
genin labeled sense probe. Bar ¼ 200 lm.
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Fab fragments conjugated with alkaline phosphatase. The bands were
visualized using a chromogenic substrate for alkaline phosphatase.
Fluorescence in situ hybridization
Male Wistar rats were anesthetized and perfused transcardially with
normal saline followed by buffered paraformaldehyde (4%, w/v;
200 mL/rat) prior to the removal of the brain. Different regions of
human brain (cortex, cerebellum, hippocampus) obtained at autopsy
were dissected out and fixed in buffered paraformaldehyde as above.
The tissue was processed for paraffin embedding and serial sections
(8–10 lm thick) were cut under RNase-free conditions. Sections
were dewaxed, hydrated in graded ethanol, acetylated, and treated
with proteinase K. Sections were then rinsed in phosphate-buffered
saline (PBS) and dehydrated using graded ethanol. Digoxigenin-
labeled antisense and sense cRNA (for control sections) were
synthesized from Cyp1a1 cDNA using T7 and SP6 RNA polym-
erases, respectively. Sections were hybridized overnight at 50C
with sense or antisense probes. After hybridization, sections were
washed, incubated with blocking reagent (0.5%, w/v, NEN Life
Sciences) and then with antibody to digoxigenin conjugated to
horseradish peroxidase. After washing, sections were incubated with
biotinylated tyramide followed by streptavidin fluorescein. Finally,
sections were washed, dried and counterstained with Evan’s Blue
prior to examination under a fluorescence microscope.
RT–PCR analysis of RNA from rat and human brain cortex
Total RNA was isolated from brain and liver of rats, human brain
cortex, and liver obtained at autopsy as described above. The first
strand of cDNA was synthesized using 1 lg of total RNA from
human brain, oligo dT primers and reverse transcriptase. The
second strand was synthesized using T4 DNA polymerase.
Double-stranded DNA was purified by phenol/chloroform
Fig. 3 Localization of CYP1A1 mRNA in human brain by fluorescence
in situ hybridization. (a) Intense fluorescence was observed in the
dentate gyrus (arrowhead) region of the hippocampus. Staining of the
interneurons of the hilus (arrow) was also observed. Bar ¼ 100 lm.
(b) Higher magnification of CA3 neurons shows the expression of
CYP1A1 mRNA in the hippocampus. Bar ¼ 25 lm. (c) The control
section hybridized with sense probe. Bar ¼ 100 lm. (d) The presence
of CYP1A1 mRNA in the pyramidal neurons of the CA1 subfield in the
hippocampus. Inset: Higher magnification of CA1 neurons. (e) Higher
magnification of the granule cells in the dentate gyrus. Bar ¼ 25 lm.
(f) Intense fluorescence was seen in the CA3 pyramidal cell layers of
the human brain. Bar ¼ 100 lm. (g) Robust staining of the CA2
pyramidal cell layer of the human brain shows the presence of
CYP1A1 in human brain. (h) Similar section of hippocampus
hybridized with the sense probe. Bar ¼ 100 lm. (i) Intense fluores-
cence was seen in neuronal cell layers of the human brain frontal
cortex. Differential fluorescence was seen delineating the laminar
architecture of the cortex. Inset shows the higher magnification of
cortical neurons. Bar ¼ 200 lm. (j) Fluorescent labeling of the
Purkinje cells (arrow) and the granule cell layer (GL) in human cere-
bellum indicating the presence of CYP1A1 mRNA. Sparse staining of
the cells in the molecular layer (ML) was also noted. Bar ¼ 100 lm.
Higher magnification of a Purkinje neuron is shown in the inset.
(k) Another view of cerebellum showing the expression of CYP1A1.
The arrow shows the labeling of Purkinje neurons. Neurons in the
granule cell layer (GL) were also stained. Bar ¼ 200 lm. (l) Sparse
staining was observed in the reticular neurons of the midbrain region.
Bar ¼ 200 lm.
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extraction and alcohol precipitation and then used as template for
PCR. The primers used for amplification of CYP1A1 (GenBank
Accession No. K03191) were 5¢- to 3¢-TGGATGAGAACGCCA-
ATGTC (representing bases from 967 to 986) and 5¢- to 3¢-
TGGGTTGACCCATAGCTTCT (representing bases from 1358 to
1339) and expected size of the PCR product was 392. cDNA
synthesized from 1 lg of total RNA was suspended in 5 lL of
10 mM Tris–HCl (pH 8.3) and added to the final reaction mixture
which contained 50 mM KCl, 200 lM of each dNTP, MgCl2
(2.5–3.5 mM), primers (80–85 pmole), and 0.25 units of Amp-
liTaq DNA polymerase. The thermal cycling conditions used for
CYP1A1 were as follows: initial denaturation at 94C for 5 min
followed by 40 cycles consisting of 30 s at 94C, 30 s at 60C
and 60 s at 72C with a final extension at 72C for 2 min.
Negative control consisted of sterile water instead of template
DNA. The PCR products (20 lL) were separated by electrophor-
esis using 1.2% agarose gel and stained with ethidium bromide.
The identity of PCR products was confirmed by sequencing. The
following primers, forward 5¢- CACATCCGGGACATCACAG-3¢
(representing bases from 913 to 931) and reverse 5¢-GTCTCCCC-
AATGCACTTTCG-3¢ (representing bases from 1447 to 1466)
were used to amplify the region exon 3–7 of rat brain and liver
Cyp1a1 cDNA (GenBank Accession No. NM_012540). The
anticipated size of the amplicon is 554 bp.
Immunohistochemistry
Paraffin-embedded sections of rat and human brain were prepared
as described above. Sections were dewaxed and transferred to
PBS containing hydrogen peroxide (3% v/v) to block the
endogenous peroxidase reaction. The sections were pressure
cooked in sodium citrate buffer (0.01 M, pH 6) for antigen
retrieval, blocked with normal goat serum and incubated with
antiserum to P-450 1a1 (Anandatheerthavarada et al. 1990).
Control sections were incubated with non-immune serum. The
sections were washed, treated with biotinylated anti-rabbit IgG,
and incubated with VECTASTAIN-Elite ABC reagent. Color was
developed, using diaminobenzidine and hydrogen peroxide. The
sections were washed in water, dehydrated in graded ethanol,
cleared with xylene, dried, and mounted in Permont.
Homology modeling of human brain variant P-450 1A1
The homology models of human brain variant P-450 1A1 and liver
P-450 1A1 were constructed using mammalian CYP2C5 bound
to 4-methyl-N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)benzenesulfon-
amide (DMZ) crystal structure coordinates (1 N6B) as template
(Wester et al. 2003). Unlike the original CYP2C5 PDB file (1DT6),
this template does contain coordinates for the FG loop region.
Alignments followed that of Szklarz and Paulsen (2002, Fig. 9) and
MODELLER (Sali and Blundell 1993) was used for generation of
the models. Ten models were generated for each protein and the best
as determined by inspection and PROCHECK (Laskowski et al.
1993) were chosen for further molecular dynamic simulations.
Psfgen utility within NAMD (Kale´ et al. 1999) using CHARMM22
forcefield parameters allowed creation of psf and pdb files needed
for simulations. The models were solvated with water using the
program VMD (Humphrey et al. 1996) and coordinates transferred
back to NAMD for energy minimization and simulated annealing.
Particle Mesh Ewald (PME) algorithm was used to deal with
long-range electrostatics using a grid size of 80 · 80 · 80. A
dielectric constant of 1 was used. The systems were minimized for
20 000 steps using the conjugate gradient method. The simulated
annealing protocol followed minimization by rapidly heating the
systems to 550 K in 6 ps and maintaining at 550K for an additional
6 ps. They were slowly allowed to cool from 550 K to 0 K in 24 ps.
All figures were generated with Swiss PDB Viewer and rendered for
publication quality in POVRAY 3.5 (Guex and Peitsch 1997).
Results
Northern blot analysis of Cyp1a1/CYP1A1 expression in
rat and human brain
Northern blot analysis of mRNA from rat brain cortex and
cerebellum, and human brain cortex from three subjects
using the cDNA to Cyp1a1 revealed the constitutive
expression of CYP1A1 mRNA in both rat and human brain.
The relative mobility of the transcript was similar to 18S
ribosomal RNA (depicted by arrow in Figs 1a and b). The
relative size of 18S rRNA is approximately 1.6 kb. This was
similar to that seen in rat liver (Fig. 1a).
Localization of Cyp1a1 mRNA in rat brain by
fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) studies demon-
strated the presence of Cyp1a1 mRNA predominantly in
neuronal cells in rat brain regions when hybridized with
the riboprobe synthesized from the cDNA to Cyp1a1. High
levels of Cyp1a1 mRNA expression were seen in olfactory
bulb, thalamus, cerebral cortex, and hippocampus. The
neurons in the cerebral cortex showed intense cytosolic
staining, indicating the presence of Cyp1a1 mRNA
Fig. 4 Immunoblot analysis of microsomal protein from rat (a) and
human (b) brain regions stained with antiserum to brain P-450 1a1.
Microsomal protein (50 lg) prepared from rat (a) and human (b) brain
regions were subjected to SDS–PAGE followed by immunoblotting
onto nitrocellulose membrane with antiserum to P-450 1a1. (a) The
lanes contained microsomal protein from rat brain cortex (lane 1),
cerebellum (lane 2), brain stem (lane 3), hippocampus (lane 4), stri-
atum (lane 5), thalamus (lane 6), and whole brain (lane 7). (b) Im-
munostained bands were also detectable in microsomes from human
brain regions such as striatum (lane 1), thalamus (lane 2), hipocampus
(lane 3), cortex (lane 4), cerebellum (lane 5), and midbrain (lane 6).
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(Fig. 2a). The laminar architecture of different cortical
layers was clearly seen in the sections hybridized with
antisense probe. In the cerebellum, Purkinje cells showed
intense fluorescence, while interneurons of the molecular
layer (ML) were relatively less stained (Fig. 2b). In
midbrain, the reticular neurons were selectively labeled,
indicating the predominant presence of Cyp1a1 mRNA
within this cell population (Fig. 2c). There was only sparse
staining of neurons in the striatum (Fig. 2d), whereas
control sections hybridized with sense probe did not show
any fluorescence (data not shown). Intense fluorescence
was seen in hippocampus in the pyramidal neurons of
CA1 and CA2 and in granule cell layer in the dentate
gyrus (Fig. 2e). The control sections hybridized with the
sense probe did not show any fluorescence (Fig. 2i).
Thalamic neurons were stained intensely showing expres-
sion of Cyp1a1 mRNA (Fig. 2f). The corresponding
control sections hybridized with sense probe are shown
in Fig. 2(j). In olfactory lobe, neurons in glomeruli were
intensely labeled (Fig. 2g). The anterior horn cells of the
spinal cord were intensely fluorescent, indicating expres-
sion of Cyp1a1 mRNA (Fig. 2h), whereas control sections,
olfactory and spinal cord, hybridized with the sense probe
did not show any fluorescence (Figs 2k and l). All sections
were counter stained with Evan’s Blue.
Localization of CYP1A1 mRNA in human brain by FISH
FISH studies demonstrated the presence of CYP1A1
mRNA predominantly in neuronal cells in the human
brain regions. The granule cells in dentate gyrus (Figs 3a
Fig. 5 Localization of P-450 1a1 in rat brain by immunohistochemis-
try. Immunostaining of cortical neurons in rat brain showing the
expression of P-450 1a1 protein. Intense labeling of apical dendrites
was observed in the cortical neurons. Bar ¼ 10 lm. (b) Immuno-
staining of the granule cell layer of cerebellum was seen. Higher
magnification of cerebellum showing intense staining in Purkinje cells
indicating the presence of P-450 1a1. Bar ¼ 10 lm. (c) Intense
immunostaining of reticular neurons in midbrain showing the presence
of P-450 1a1 in rat brain. Bar ¼ 10 lm. (d) Immunostaining was
observed in the neurons of glomeruli (arrow) demonstrating the
presence of the P-450 1a1 protein. Bar ¼ 200 lm. (e) Immunostaining
was seen in the CA1 pyramidal neurons of the hippocampus indicating
the presence of P-450 1a1 protein. The axonal processes of neurons
were labeled intensely. Bar ¼ 10 lm. (f) Expression of P-450 1a1
seen in the neurons of thalamus. Bar ¼ 10 lm. (g) Intense staining of
striatal neurons observed when rat brain sections were treated with
P-450 1a1 antiserum. Bar ¼ 10 lm. (h) Intense immunostaining was
seen in anterior horn cells of spinal cord for P-450 1a1 antiserum.
Bar ¼ 10 lm. (i) Control section of hippocampus treated with non-
immune serum did not show any staining. Bar ¼ 200 lm. (j) No
staining was seen in similar section of thalamic region incubated with
non-immune serum. Bar ¼ 200 lm. (k) No staining was observed in
striatal section incubated with non-immune serum. Bar ¼ 200 lm.
(l) Control section of spinal cord incubated with pre-immune serum did
not show any staining. Bar ¼ 200 lm.
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and e) and pyramidal neurons in CA3 region of hippo-
campus were stained (Figs 3b and f), while control
sections hybridized with sense probe did not show any
fluorescence (Figs 3c and h). Pyramidal neurons in CA1
(Fig. 3d) and CA2 (Fig. 3g) were intensely stained. High
levels of CYP1A1 mRNA were seen in neuronal cells in
frontal cortex (Fig. 3i). In the cerebellum, Purkinje cells
and the granule cell layer showed significant fluorescence
(Figs 3j and k). Occasional staining was seen in the
molecular layer. In the midbrain, reticular neurons were
stained, although not as intensely as seen in the cerebellum
and cortex (Fig. 3l). Thus, there was specific neuronal
labeling while other cell populations did not show any
fluorescence indicating the selective localization of
CYP1A1 mRNA in human brain.
Immunoblot analysis of microsomes from rat and human
brain using antiserum to hepatic P-450 1a
Immunoblot analysis of rat brain microsomal proteins using
antiserum to P-450 1a1 showed the constitutive presence of
P-450 1a in different regions of rat brain (Fig. 4a). Similar
immunoblot studies were carried out using microsomes
prepared from human brain regions obtained at autopsy
(Fig. 4b). The constitutive presence of P-450 1A1 was
detectable in all the human brain regions examined. An
immunoreactive protein of molecular weight approximately
55 kDa was detectable in microsomes prepared from various
regions of human brains such as cortex, cerebellum, striatum,
and hippocampus. Another band of slightly lower molecular
weight was also seen in both rat and human brain. This band
could represent P-450 1a2/1A2 or a proteolytic product of
P-450 1a1/1A1.
Immunohistochemical localization of P-450 1a1 in rat
brain
Immunohistochemical studies demonstrated the presence of
P-450 1a1 protein predominantly in neuronal cells in rat
brain. A higher magnification of cortical neurons in rat brain
showing the expression of P-450 1a1 is depicted in Fig. 5(a).
Intense labeling of apical dendrites was observed in cortical
neurons. Staining of Purkinje and granular cells was
observed when sections were incubated with antiserum
P-450 1a1 (Fig. 5b). Expression of P-450 1a1 was also seen
in midbrain reticular neurons. Intense immunostaining was
seen in apical neurites of reticular neurons (Fig. 5c). The
neurons in the olfactory glomeruli were intensely stained
(Fig. 5d). Immunostaining was observed in CA1 pyramidal
Fig. 6 Immunohistochemical localization of P-450 1A1 in human brain
frontal cortex and midbrain using antiserum to P-450 1a1. (a) Intense
immunolabeling of neurons in frontal cortex was seen indicating the
presence of P-450 1A1. The apical dendrites were also stained.
Bar ¼ 10 lm. (b) Immunostaining of reticular neurons in the midbrain
indicating the presence of P-450 1A1 observed. Bar ¼ 10 lm.
(c) Localization of P-450 1A1 in the granule cells (arrowhead) and
Purkinje cell (double arrow) is depicted. Bar ¼ 10 lm. (d) Immuno-
staining of CA1 pyramidal neurons indicating the presence of P-450
1A1. Bar ¼ 10 lm. (e) No staining was seen in cerebral cortex section
incubated with non-immune serum. Bar ¼ 100 lm. (f) A similar sec-
tion of midbrain treated with non-immune serum did not show immu-
nostaining. Bar ¼ 100 lm. (g) Control section incubated with non-
immune serum did not show immunostaining in the cerebellum. Bar ¼
100 lm. (h) Similar section treated with non-immune serum did not
show immunostaining of the CA1 neurons. Bar ¼ 100 lm.
730 S.J. Chinta et al.
 2005 International Society for Neurochemistry, J. Neurochem. (2005) 93, 724–736
neurons of hippocampus (Fig. 5e) showing the presence of
P-450 1a1 in rat brain. The neurites of CA1 neurons were
intensely labelled. P-450 1a1 expression was also seen in
neurons of the anteroventral nucleus of thalamus (Fig. 5f).
Intense immunostaining was observed in striatal neurons,
indicating the presence of P-450 1a1 protein (Fig. 5g).
Intense staining of anterior horn cells in spinal cord
demonstrated the expression of P-450 1a1 (Fig. 5h), whereas
similar sections pre-treated with non-immune serum did not
show any staining (Figs 5i–l).
Localization of P-450 1A1 in human brain
Immunohistochemical analysis using antiserum to rat liver
P-450 1a1 demonstrated the predominant presence of
P-450 1A1 in a neuronal population in human brain in
concordance with in situ experiments. Intense staining of
the neuronal cell body and apical dendrites was seen in
frontal cortex (Fig. 6a). Reticular neurons of the midbrain
(Fig. 6b) were also intensely immunostained. Similar
sections incubated with non-immune serum did not show
any staining (Figs 6e and f). In the cerebellum, granule
cells and Purkinje cells were stained (Fig. 6c), with the
granule cells being more intensely stained compared to
Purkinje cells. The CA1 neurons in the hippocampus were
also stained although less intensely than in the cerebellum
(Fig. 6d).
RT–PCR analysis of RNA from rat and human brain
cortex
RT–PCR analysis of the cDNA prepared from human brain
RNA from 13 subjects, yielded a 305-bp fragment instead of
the expected 392-bp product, indicating the presence of a
splice variant of CYP1A1 in human brain (Fig. 7a). The
sequencing of the RT–PCR product revealed complete
sequence identity with CYP1A1 in the amplified region
except that it lacked exon 6. We were able to amplify brain
and liver RNA from the same individual. The exon 6 deleted
RT–PCR product (305 bp) was detected only in the brain; the
amplicon from liver RNA yielded a product of having
392 bp, indicating the presence of exon 6 (Fig. 7b). Thus, the
unique splice variant having exon 6 deletion is present only
in the brain and not in the liver from the same individual.
Amplification of the same region of the rat brain and liver
Cyp1a1 yielded a 554-bp product, which was the expected
size indicating that exon 6 was intact in Cyp1a1 gene in both
rat brain and liver (Fig. 7c).
3D structure modeling
In order to evaluate the potential differences in the active site
and/or substrate access channel, P-450 1A1 and P-450 1A1
variant structural models were compared. Both models were
prepared with the program MODELLER using the P-450
2C5 template coordinates bound to DMZ. The alignment
used is shown in Fig. 8, and followed that of Szklarz and
Fig. 7 RT–PCR amplification of cyp1a1 and CYP1A1 in rat and
human brain. (a) Total RNA was extracted from autopsy human brain
samples and RT–PCR reaction was carried out using primers specific
to human liver CYP1A1. PCR amplified DNA was separated by
agarose gel electrophoresis and stained with ethidium bromide. Exons
3–7 of the CYP1A1 gene was amplified by RT–PCR in 13 samples of
human brain cortex obtained at autopsy. An amplicon of 305 bp was
detected in all the samples indicating the deletion of exon 6.
(b) RT–PCR amplification of exons 3–7 using RNA from liver (lane 2)
and cerebral cortex (lane 1) from the same individual resulted in two
different products having 392 and 305 bp, respectively. (c) Exons 3–7
of the Cyp1a1 gene was amplified by RT–PCR using RNA from rat
brain (lane 1) and liver (lane 2). An amplicon of 554 bp was detected in
both the samples indicating the presence of exon 6. ‘M’ indicates
molecular weight markers. ‘Ne’ indicates negative control.
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Paulsen (2002) for P-450 1A1. Figure 9 demonstrates the
quality of the final models showing plots of the distance
variation between the Ca carbons of the homology models
and those of the P-450 2C5 template coordinates using
PROFIT (http://www.bioinf.org.uk/software/profit/) The
fitting in PROFIT uses the McLachlan algorithm (McLachlan
1982). The graphs show typical variances in coordinates
based on the identity and similarity between the query
sequences and the template. The overall Ca carbon RMSD
PROFIT calculation based on the alignment in Fig. 8 of
P-450 2C5 versus P-450 1A1 and brain variant P-450 1A1
was 2.21 and 2.97. The structure near the active site and
substrate access channel of human brain variant P-450 1A1
appears considerably different from the well-characterized
hepatic P-450 1A1 as shown in Fig. 10(a). One major
structural difference noticed lies in the main substrate access
channel, which has been defined as being lined by the loop
between the F and G helices, b-sheets 1 and 4, and the B¢
helix through X-ray crystal studies of bacterial P-450s
(Peterson and Graham-Lorence 1995). This channel appears
to have shifted in the human brain variant P-450 1A1 as
compared to that in P-450 1A1, probably due to a
compensatory effect of the protein trying to fill in the void
created by the deletion (Fig. 10a). This movement of the
substrate access channel could consequently alter the
approach angle for substrate to the active site. The substrate
access channel itself in the human brain variant P-450 1A1
appears widened. Further, the substrate binding sites, inclu-
ding SRS5 and SRS6, appear more open in the variant
(Fig. 10b), which may allow it to accommodate larger and
not so restrictive substrates like polyaromatic hydrocarbons
that are typical P-450 1A1 substrates. A comparison of the
structure of the loops adjacent to the deleted regions liver and
brain variant of P-450 1A1 is depicted in Fig. 11. These
loops provide the flexibility to allow H352 and Q382 (Q353
in brain variant) to come into the general vicinity of one
another without large structural consequences in the brain
variant where S353-D381 is missing.
Discussion
The constitutive expression of CYP1A1 in rat and human
brain has been demonstrated by RT–PCR amplification of
selected regions in the CYP1A1 gene (Hodgson et al. 1993;
Schilter and Omiecinski 1993; Geng and Strobel 1997; Yun
et al. 1998; McFayden et al. 1998). In the present study, we
demonstrate constitutive expression of full-length mRNA
transcript of approximately 1.6 kb by northern blot analysis
using mRNA from rat and human brain cortex (Figs 1a and
b) and thus provide the first evidence for the expression of
full-length mRNA of CYP1A1 in rat and human brain. Due
to autolytic changes that occur during post-mortem delay,
there was partial degradation of RNA as seen from the
presence of lower molecular weight products in northern blot
of human brain cortex from the two subjects. However,
despite this, substantial expression of CYP1A1 mRNA was
detectable in the northern blots performed using poly-(A+)
RNA from autopsy tissue (Fig. 1b). Earlier studies from our
laboratory have demonstrated that the integrity of mRNA and
protein in brain is maintained to a large extent when tissues
are obtained within 12 h of post-mortem delay (Chinta et al.
2002).
Localization of constitutively expressed CYP1A1 in rat
and human brain using FISH demonstrates the differential
Fig. 8 Amino acid sequence alignment of
CYP2C5, CYP1A1, and brain variant
CYP1A1. The secondary structural
elements are shown as a-helices (green
highlights) and a-sheets (purple highlights).
Substrate recognition sites 1–6 (SRS) are
represented by underlines.
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expression of CYP1A1 mRNA in different regions of brain.
Throughout the brain, intense cytosolic fluorescence was
observed in specific subtypes of neuronal cells such as the
cortical neurons, pyramidal neurons of hippocampus, granule
cell layer of the dentate gyrus, Purkinje cells of the
cerebellum, reticular neurons of midbrain. While specific
cell populations such as Purkinje and granule cells were
labeled in the cerebellum, the cells in the molecular layer did
not show any evidence for the presence of CYP1A1 or
Cyp1a1. The presence of CYP1A1 in selective cell types is
of interest, particularly because CYP1A1 and Cyp1a1 are
induced by exposure to polycyclic aromatic hydrocarbons,
which can cross the blood–brain barrier. Thus, the predom-
inant expression of CYP1A1 in neurons, especially pyram-
idal neurons of hippocampus in both rat and human brain, is
of special interest, as P-450 1A1 can generate reactive
oxygen species, such as superoxide anion, hydroxyl radical,
and hydrogen peroxide (Liu et al. 2001); and hippocampal
neurons are especially vulnerable to oxidative stress-medi-
ated injury such as that seen during reperfusion following
cerebral ischemia (Shivakumar et al. 1995). Because hippo-
campus plays an important role in cognitive functions, such
as learning and memory, damage to this area of the brain
could potentially have serious consequences in humans.
Immunoblot analysis of microsomes from various regions
of rat and human brain showed expression of P-450 1A1
immunoreactive protein, indicating the constitutive expres-
sion of P-450 1A1 protein in brain. These results are in
agreement with our earlier reports (Anandatheerthavarada
et al. 1990) and those from other laboratories (Kapitulnik
et al. 1987; Kohler et al. 1988; Geng and Strobel 1997) but
in contrast to the reports from some laboratories where they
were unable to detect the Cyp1a1 protein in rat brain (Morse
et al. 1998). Recently, Huang et al. (2000) have also
demonstrated the constitutive expression of Cyp1a1 in the
rat CNS by RT–PCR. These studies also showed the
induction of Cyp1a1 by tetrachlorobenzo-p-dioxin in hypo-
thalamus, hippocampus, cortex, cerebellum, and substantia
nigra in rat brain. The subcellular localization of CYP1A1
mRNA and its role in the metabolism of the intravenous
anesthetic agent propofol was also reported in human brain
(Zhang et al. 2001). The present study for the first time
demonstrates the simultaneous detection of CYP1A1 mRNA
and protein using in situ hybridization and immunohisto-
chemistry in neuronal cell populations. Localization of
CYP1A1 predominantly in the neurons as seen in the present
study may have adverse effects in terms of bioactivation of
procarcinogens into reactive metabolites and increase in the
generation of reactive oxygen species, which may cause
oxidative damage in the brain.
RT–PCR amplification of the CYP1A1 gene using total
RNA from 13 human brain autopsy samples yielded a
fragment of 305 bp instead of the expected 392 bp (Fig. 7a).
The human CYP1A1 gene has a total of seven exons, of which
we amplified exons 3–7. The sequencing of the RT–PCR-
amplified product showed complete loss of exon 6, while the
rest of the sequence had 100% identity with the human
CYP1A1 gene. All the 13 human brain samples tested showed
loss of exon 6 of the CYP1A1 gene. However, a larger number
of samples need to be tested to determine if the loss of exon
6 is a common feature of the CYP1A1 enzyme in human
brain. Interestingly, the splice variant was detected only in the
brain but not in the liver from the same individual. P-450
levels in brain and liver are altered differentially during post-
mortem delay (Chinta et al. 2002), therefore it is difficult to
quantitate the relative abundance of the transcript in liver and
Fig. 9 Distance variation in Ca backbone position in (a) P-450 2C5
(1 N6B) versus P-450 1A1 liver model and (b) P-450 2C5 (1 N6B)
versus P-450 1A1 brain variant model. PROFIT was used to give a by-
residue distance difference analysis from the least squares fit of the
two models compared to the template P-450 2C5 coordinates used to
generate the models. The zones used for initializing the superimpo-
sition were supplied from the alignment in Fig. 8 and fitted based on
Ca carbons. The overall Ca carbon RMSDs were 2.051 A˚ and 2.354 A˚
for liver and brain variant P-450 1A1, respectively. The abscissa
represents the P-450 2C5 residue number. The P-450 2C5 residue
numbers without a corresponding Ca carbon in liver or brain variant
P-450 1A1 are seen as breaks in the data, which essentially depicts
gaps in the structural alignment.
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brain from the same individual as liver P-450 levels decrease
more rapidly by autolytic cleavage during post-mortem delay
compared to brain P-450.
The nervous system has a propensity for generating
alternate spliced forms, and splicing defects may not be
related to differences in the genomic sequence but may be
regulated by mechanisms involving the spliceosomal com-
plex and RNA binding proteins, which are poorly understood
(Grabowski and Black 2001). The tendency for human brain
to generate alternate spliced genes as seen in the present
Fig. 10 3D homology modeling of CYP1A1 and CYP1A1 brain vari-
ant. Comparison between CYP1A1 liver form structure (blue) and
CYP1A1 brain variant (gray). A homology model of CYP1A1 and the
brain variant was constructed based on the crystal structure coordi-
nates of mammalian P-450 2C5 complexed to sulfaphenazole. These
models generated by MODELLER were superimposed to give the
exact same viewing angle in both proteins with respect to the heme
(red). The light blue regions denote the area deleted on CYP1A1
variant. (a) There is a remarkable movement of the substrate access
channel in the variant compared to CYP1A1. This structural pertur-
bation in the variant may alter the accessibility of substrates to the
active site. Arrow represents direction of access channel. (b) This
region of the active site shows CYP1A1 more compact over the heme,
whereas the variant appears more relaxed. SRS5 is represented by
F345, V346, I350, and SRS6 by T461 and M462. Further, this variant
may be adapted to accommodate a wider range of substrates (i.e.
nonplanar compounds).
Fig. 11 Deleted region comparison of liver and brain variant P-450
1A1.The liver form is shown in blue and brain variant in gray with heme
shown in red. The deleted region is removed in the liver form for clarity.
Therefore, only the loops adjacent to the deletion are represented in
liver P-450 1A1 and the corresponding residues are displayed for the
brain variant to provide a comparison between these two proteins.
F345 marks the first amino acid of the loop after the K helix and H352
(green) is the last amino acid before the deletion. Q382 (Q353 in brain
variant), shown in green, to F391 (F362 in brain variant) make up the
loop after the deletion, which is attached to the K¢ helix.
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study wherein an alternate spliced variant having exon 6
deletion was identified only in the human brain. Human
brain-specific alternate spliced forms of P-450 2D enzymes
are expressed, which mediate biotransformation of drugs by
pathways that are different from those seen in liver (Pai et al.
2004). Presumably other brain-specific alternatively spliced
P-450 enzymes may be expressed in human brain, which are
yet to be identified. In rat brain and liver, amplification of the
same region did not reveal the presence of the alternate
spliced product with exon 6 deletion, indicating that the
alternate spliced product with exon 6 deletion is present only
in human brain.
The deletion of exon 6 in CYP1A1 does not lead to
premature termination; presumably, its translation would
lead to a functional P-450 enzyme. Examination of the
sequence of the RT–PCR product, especially at the
beginning of exon 7, indicates that there is no frame shift
as compared to CYP1A1. The structural modeling of the
putative protein indicates that there would be alteration in
the substrate access channel possibly allowing for less
restricted access and altered angle of approach as
compared to the normal CYP1A1. The deleted region
begins within the a1–4 sheet and extends through the
K¢-K¢ loop. It seems reasonable that the variant could
withstand this deletion without causing a complete change
in the overall structure compared to liver P-450 1A1 given
the positioning of the two residues flanking the deletion. A
comparison of the liver and brain variant forms surround-
ing and including this region is shown in Fig. 11.
However, as noted in the alignment in Fig. 8, the deletion
includes one side of the substrate access channel, a1–4
and 1–3 sheets, and also a portion of substrate recognition
site 5. Therefore, the possibility of this deletion causing
substantial changes in substrate preference due to its
location should be noted despite not having large global
conformational differences from liver P-450 1A1. Noble
et al. (1999) have shown in P-450 BM3 that a mutation
from Phe4 2 > Ala lining the substrate access channel
proved to increase the Km for two different substrates. This
shows importance of volume considerations in substrate
access through the channel. The same type of results may
occur for the P-450 1A1 human brain variant as compared
to the P-450 1A1 liver form as the access channel appears
broader in the variant. Therefore, Ks and Km values for the
P-450 1A1 variant should decrease as compared to P-450
1A1. A broader substrate access channel would also allow
for more free movement of the substrate within the access
channel, which could likely lead to the formation of more
than one metabolite. P-450 1A1 is one of very few P-450
enzymes with a high degree of preference for flat planar
molecules as substrates; for example, polyaromatic hydro-
carbons. Size of the active site, character of the substrate
access channel, and angle of approach are among the
characteristics, which establish substrate preference. As
cited in the Results section, these characteristics appear
altered in the P-450 1A1 variant such that the variant may
be more suited to substrates other than flat planar
molecules. Our modeling studies confirm that a portion
of SRS5 is absent and the residues approximating the
position of SRS5 in hepatic P-450 1A1 are non-analagous,
supporting the prediction of a less restrictive active site.
The current models suggest candidate sites or residue
mutations to evaluate the role of SRS5 in substrate
binding. Further, replacing the missing stretch with non-
homologous polypeptides may allow us to evaluate the
specificity or non-specificity of chain composition in the
substrate access channel or size of the active site. The
cloning and expression of this variant, subsequent genera-
tion of mutants, and binding/kinetic studies currently in
progress would help address the above and further refine
the 3D homology models.
In conclusion, the study demonstrates the presence of
alternate spliced forms of P-450 in human brain. The
presence of as yet unidentified P-450 enzymes generated
by alternate splicing would help understand the specific
biotransformation pathways occurring at the target site of
action of drugs.
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